PartnershipApr 9, 2026, 04:26 PM
Emergent BioSolutions Partners with B.C. PHSA to Supply NARCAN® Nasal Spray Following $18M CAD Government Investment
AI Summary
Emergent BioSolutions announced a partnership with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for British Columbia's Take-Home Naloxone Program. This collaboration follows an additional $18 million CAD investment by the B.C. government to expand the program, building on a 2024 pilot that distributed 60,000 nasal naloxone kits. The agreement strengthens Emergent's presence in the Canadian public health sector, leveraging its existing Canadian footprint with over 300 employees, and contributes to the company's mission of combating the opioid crisis by increasing access to life-saving products. The rollout of NARCAN® Nasal Spray across the province is set to begin this month.
Key Highlights
- Emergent BioSolutions partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program).
- The partnership follows an additional investment of $18 million CAD by the B.C. government to expand the BC THN Program to include nasal naloxone.
- This initiative expands on B.C.'s nasal naloxone pilot program, launched in 2024, which provided 60,000 nasal naloxone kits to various community sites.
- Emergent has delivered more than 100 million doses of NARCAN® Nasal Spray to people, communities, and businesses across Canada and the U.S. since 2016.
- Emergent maintains a significant Canadian footprint with over 300 employees across its Winnipeg, Manitoba manufacturing facility and offices in Mississauga, Ontario.
- NARCAN® Nasal Spray is already accessible at no cost to residents of Ontario, Quebec, Nova Scotia, Northwest Territories, Nunavut, and Yukon, and through federal programs like Veteran Affairs Canada, First Nations Health Authority (FNHA), and Non-Insured Health Benefits (NIHB).